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Abstract
Clinical translation in the field of regenerative medicine means ma-
nufacturing a safe, reproducible and effective clinical product for the 
benefit of patients. This represents the ultimate goal of applied re-
search, but beyond researchers and clinicians, multiple intermediate 
players are involved, including other researchers, reviewers, funding 
agencies, scientific societies, guideline authors, and policy regulators. 
Consequently, bridging translational research and regenerative me-
dicine therapies into the 21st Century requires a resolute effort. We 
envisage that strategic and synergistic efforts in seven key areas will 
facilitate the mainstream adoption and implementation of regenera-
tive medicine based therapies.
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Background
Nowadays biomedical research focused on regenerative medicine 
therapies is afflicted more than ever by an awkward paradox: several 
apparently striking discoveries turn out to be utterly non influential 
in the setting of real-world point of care of our patients. Specifically, 
we are faced with a plethora of small or moderately-sized trials of 
different quality, sometimes challenging each other and often not 
able to generate robust scientific evidence with an immediate im-
pact on healthcare. The result is that researchers, clinicians and also 
patients are pushed in different directions, and such dissimilar effect 
estimates highlight mixed results with benefits ranging from absent 
to transient or, at most, marginal [1]. 
Clinical translation, which means  a safe, reproducible and effec-
tive clinical product/protocol  for the benefit of patients, is the ul-
timate goal of applied research, but beyond researchers and cli-
nicians, multiple intermediate players are involved, including other 
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researchers, reviewers, funding agencies, scientific 
societies, guideline authors, and policy regulators. 
However, to date, the mainstay of the entire field 
has largely been the extended and often excee-
dingly liberal use of small-sized clinical trials, as 
well as the dispersion in preclinical or clinical re-
search due to poor assessment of the value of 
analytical methods –e.g., factorial designs, large 
simple studies, and longer-term follow-up of com-
pleted studies– which might have low incremental 
cost compared to the information yield. Probably 
lower costs and stronger results could arise from 
better allocation of available resources, from more 
intense exploitation of systematic reviews to select 
high-priority scientific questions and from better 
study design and interpretation of final results.
How can biomedical research adapt and cope 
with this challenging scenario in order to produce 
solid and informative data to answer and possibly 
solve, at least in part, the problems burdening so-
ciety and individuals? And how could biomedical 
research become easily available and not exclusi-
vely reserved to developed countries? We believe 
that these simple questions hold the entire heart 
of the matter.
More poignantly, bridging regenerative medici-
ne therapies ahead requires a resolute effort. We 
envisage that strategic and synergistic efforts in 
seven key areas may strongly facilitate the mains-
tream adoption and implementation of regenerati-
ve medicine based therapies. These areas include: 
(1) the field of regenerative medicine, (2) public-
private partnerships, (3) improved regulatory stan-
dards, (4) advanced manufacturing systems, (5) ex-
tensive networking,  (6) integrated databases and 
(7) widespread banking.
Discussion
Field of action of regenerative medicine
The real biological potential of many stem cell 
types seems the main limiting issue to the deve-
lopment of proper cell-based strategies intended 
for regenerative medicine. Hence, the first step 
should be a rigorous and thorough redefinition 
of the anatomy, nature, identity, location, phe-
notype and potency of non-embryonic progenitor 
cells. Recently, the extremely liberal use of stem 
cells (adopted both, as a biological concept, as 
well as the most popular tool in regenerative me-
dicine) represents one of the key difficulties of 
cell-based regenerative approaches. For example, 
MSCs (precursors of bone, cartilage, fat and fi-
broblasts) have been almost universally regarded 
as a ubiquitous cell type endowed with a broad, 
even unrestricted potency. A canonical line in the 
introduction of virtually every paper in the field 
evokes their widely assumed, and yet never ri-
gorously proven, ability to generate a number of 
other nonskeletal mesoderm derivatives, such as 
muscle or endothelial cells, and even a number 
of non-mesodermal cell types, such as neurons 
or liver cells. Many of the events depicted in vitro 
(clonal growth) and in vivo (differentiation toward 
cartilage or muscle, assembly of blood vessels, 
recruitment of mesodermal progenitors to a mi-
crovascular niche, pattern formation) not always 
correspond to real therapeutic benefits after cli-
nical translation, with results ranging from absent 
to marginal. In reality the scientific community 
is remote from solving this Gordian knot, since 
more fundamental biological questions arisen 
from pre-clinical animal models (cells interaction 
or coupling with other cells, grow, differentiation, 
creation of patterns, real tissue generation, pa-
racrine effects, apoptosis)  still have to be fully 
addressed in order to overturn events defined as 
“stochastics” and yet, in essence, not understood 
into unquestionable. 
Public-private partnerships
Building a solid cooperative relationship between 
public entities, such as state universities and private 
institutions and companies, by means of incentives 
for public-private partnerships to advance regene-
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rative medicine, is unquestionably paramount [2]. 
Right now, ‘‘Horizon 2020’’ has to be seen as an 
opportunity to chase a common and structured 
research policy at European level,
strengthening existing programs and genera-
ting new ones within academia and industry by 
accommodating established partnerships between 
universities and industry. Consistent with ‘‘Horizon 
2020’’, these types of partnership bring together 
the very best leaders and innovators in the field, 
who have the collective expertise to translate ba-
sic science discoveries into clinically and commer-
cially available products. No single individual, nor 
any single company/institution alone could likely 
be as proficient in performing this task. This can 
be appreciated also by comparing countries with 
only a national public health system to those with 
private healthcare or hybrid systems: public uni-
versities and governments alone are most likely 
unable to support the development ‘from bench 
to bedside‘ of advanced, expensive and experi-
mental treatments, while private investors and in-
terests are often useful to reach market scale of 
biotechnological products. Becoming aware of this 
premise is a critical step toward the adoption of a 
new research model suitable for real translational 
success. These formed partnerships or consortia 
will ensure the momentous advantages of: crea-
ting mutual resources; integrating expertise from 
different disciplines toward the same objective; de-
veloping pre-competitive spaces for development 
of high-risk innovative technologies; teaching 
students and scholars; harmonizing technology 
transfer by creating master research agreements 
to facilitate collaboration and avoid common hur-
dles around patenting and intellectual property; 
developing highly-qualified expertise that can be 
used by consortium members to foster their own 
internal research efforts; creating access to shared 
facilities (e.g. clean rooms and Good Manufactu-
ring Practices [GMP] suites), as well as numerous 
other benefits. In few words, this will help bridging 
the gap between education, translational research 
and real-world point of care medicine.
Regulatory standards
A second challenge is to address the complexity of 
regenerative medicine therapies within an adequa-
te regulatory frame able to transfer innovation into 
clinical practice in a controlled and safe situation, 
protecting patients and allowing better healthcare 
at the same time. To achieve the clinical translation 
of any pharmaceutical, medical, or biotechnologi-
cal product, the development of well-defined con-
ditions for production, processing, and culture is 
required at every level. Clinical translation demands 
compliance with current GMPs for the optimization 
of cell preparation following specific protocols, such 
as avoidance of any xenogenic animal product or 
granting adequate quality standards confirmed by 
detailed protocols [3, 4, 5]. International guideli-
nes and agreements establish that pharmaceutical 
and medical device companies must comply with 
GMP criteria, and should conform their own qua-
lity standards to duly uniform themselves with the 
corresponding legislation. Stem cells are defined as 
‘advanced therapy products’, and must be handled 
and manipulated under GMP approved protocols, 
analogously to active pharmaceutical products 
(see Eudralex EU guidelines for Good Manufac-
turing Practice for Medicinal Products for Human 
and Veterinary Use), otherwise to be considered 
‘outlaw’. Therefore, full compliance with GMP is a 
mandatory aspect of stem cell-tissue engineering 
and manufacturing. Within the above mentioned 
consortia strategies, we envision a rigorous effort 
to encourage regulatory partners to develop stan-
dards to make the regulatory process more effi-
cient. Selection and optimization of the best per-
forming protocols still need to be carried out, and 
developing common references that are accepted 
by regulators for stem cells or different tissue-engi-
neered and regenerative medicine-based products, 
will enable companies to have a more systematic, 
InternatIonal archIves of MedIcIne
Section: tranSlational cardiology
Issn: 1755-7682 
2015
Vol. 8 No. 81
doi: 10.3823/1680
This article is available at: www.intarchmed.com and www.medbrary.com 4
as well as efficient process for moving a product 
forward in the clinical translation process. Com-
panies which engage in developing these regu-
latory standards will have enormous benefits by 
recommending which sets of guidance should be 
used by the entire field (including standards used 
by their competitors) to determine safety, efficacy 
and traceability in compliance with GMP guideli-
nes. Regulators will also be able to address con-
cerns and key issues with different products by 
early identifying common challenges and ensuring 
proper standards to be developed, and to enable 
safe and efficient translation of stem cell-based 
products into clinical practice without any sort of 
inference [6]. These strategies, once accomplished 
at the preclinical stage, could reduce costs and ad-
vance safer and more effective products forward 
for phase I clinical trials.
Advanced manufacturing systems
In addition to an improvement in regulatory stan-
dards, there is a need in the regenerative medicine 
field to incorporate advanced manufacturing se-
tups early on in the development of stem cell and 
tissue engineering-based technologies. Scaling-up 
to “large volumes” often generates profuse techni-
cal difficulties, resulting in intensive and time con-
suming research efforts. This clearly represents a 
restraining factor hampering the final step towards 
clinical translation for cost-effective therapies, hol-
ding back their application into common medical 
practice. Specifically one of these challenges is the 
affordable scale-up of stem cell-based therapies. 
Shifting from personal/custom-made production 
to continuous or semi-continuous processing, is 
beyond a doubt a tricky challenge. Public-private 
partnerships, combined with government-funded 
incentives, are needed to develop more automated 
manufacturing suites that align with 21st Century 
technology. State-of-the-art manufacturing labo-
ratories for allogeneic and autologous cell therapy 
that are based on disposable, closed, and automa-
ted manufacturing processes, are already available 
as prototypes, albeit at very high prices, still prohi-
bitive for most research groups and clinics worldwi-
de. Moreover, in order to provide stock biological 
products compatible with the clinical translation 
of heterologous stem cell therapy, development of 
protocols for GMP clinical-grade banking systems 
might generate readily available off-the-shelf pro-
ducts at lower costs. 
Networking
Most likely, no single company/institution could be 
so complete and skilled in performing all the abo-
ve mentioned tasks without a well-structured co-
llaborative network. Building a supportive system 
for sharing information and services among public 
and private groups having a common objective is 
mandatory in the setting of biomedical and rege-
nerative medicine research, as well as in the deve-
lopment of standardized protocols to be translated 
into clinical practice. Networking represents a pro-
blem-solving approach to the structural weakness 
of the solo approach. A close involvement of all the 
actors involved in translational research is not only 
capable of improving the efficiency of the entire 
procedure, but can also prove to be cost-effective. 
Capitalizing the specific expertise of several groups 
active in this field sharing specific skills and abilities 
such as technological (tailoring of  nanostructures 
of biopolymers for scaffold functionalization, or of 
inorganic phases, or of nanofibers) and scientific 
tools, will allow not only transferable products, but 
ways of manipulating cells and tissues, their sha-
pes, their structure. Networking thus represents 
the foreword to lay the foundations for the next 
area: the creation of integrated databases.
Integrated databases
Further important considerations will have to be 
about the development of integrated databases 
toward the concept of personalized, but also “co-
llective” medicine.  We blindly trust in  the creation 
InternatIonal archIves of MedIcIne
Section: tranSlational cardiology
Issn: 1755-7682 
2015
Vol. 8 No. 81
doi: 10.3823/1680
© Under License of Creative Commons Attribution 3.0 License 5
of cloud-based databases combining numerous 
health records and data to assist with patient care, 
research, and clinical trials. Pursuit of personalized 
medicine protocols aims for products specificity 
and dosage designed for a particular individual. 
Fully applied, it would require complete informa-
tion about the single patient, including his/her pe-
culiar responsiveness to the treatment. Data sto-
rage in dedicated databases could allow patients 
matching and enrolling in a specific trial, titration 
to the desired therapeutic effect and potential re-
duction of undesired side-effects. Moreover his/
her data might be available for the entire commu-
nity. One might conceive the following future sce-
nario: at birth a patient could have his/her blood/
tissue banked, which in turn could be screened for 
disease markers, and afterwards, if needed, ex-
ploited for the development of a stem cell-based 
autologous and/or heterologous therapy. A patient 
eligible for all inclusion criteria for a specific clini-
cal trial, could be potentially enrolled in such stu-
dy. Moreover this modernized, yet pragmatic joint 
management, could open new frontiers with the 
implication that ‘medications’ may have greater 
efficacy if administered before the onset of symp-
toms. In addition, a drug screen panel, based on 
induced-pluripotent stem cell (iPSC)-in vitro-data, 
could be used to guide the referring physician in 
the choice of the best medication, as well as on 
the responsiveness for a customized dose. All this 
information, however, would have to be stored in 
an integrated database to be used with the proper 
oversight by researchers and clinicians, to have a 
more comprehensive and personalized approach 
towards medicine. 
Banking
Stem cell and tissue engineering based-therapies 
are not always suitable for emergency scenarios. 
In the setting of acute diseases, such as myocar-
dial infarction, manufacturing protocols may re-
quire days or even weeks in order to yield the 
appropriate number of cells able to exert their 
functional benefit. Thus, development of protocols 
for clinical-grade banking systems might generate 
fully-available off-the shelf products for the clinical 
translation of cell therapy in acute settings as well. 
Yet, a tricky challenge in the setting of public bio-
banking is represented by the high costs imputable 
to the creation and maintenance of these facilities 
[7, 8] also because regenerative medicine appli-
cations for different tissues, organs and diseases, 
require different stem cells and possibly different 
banking facilities.    
Hence, the  obstacle of high cost facing the esta-
blishment of public stem cell banks has prevented 
more than a handful from opening or operating 
regularly. Considering that in an ideal world, public 
banks should not levy storage fees, many medi-
cal centers miss the funds required to establish 
and maintain them. In this scenario, as previously 
highlighted, a tight collaboration between public 
institutions and private companies could represent 
the right direction to move forward in order to 
resolve this last challenge.
Summary
We believe that these seven ambitions, if actually 
fulfilled, will truly enable stem cell and tissue engi-
neering-based technologies to be easily translated 
into clinical practice and integrated as the music of 
a gorgeous symphony. While implementing them 
effectively and in a timely fashion will be a cha-
llenge, the possible rewards can be remarkable. 
Regenerative medicine should start from a clinical 
core which is made of observations, concept and 
tools, and aim at wedding stem cell biology with 
advanced manufacturing systems, moving from 
insight to in-sight, and back. Only in this way 
stem cell and tissue engineering-based therapies 
have the potential for large-scale applications by 
healthcare systems, also possibly helping emerging 
countries to fill their gap with industrialized na-
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tions. Many reasons could explain why different re-
search areas are much more implemented in some 
countries compared to others. We could speculate 
considering  two main variables: the social envi-
ronment combined with the cultural evolution of 
the scientific knowledge, but also the politic asset. 
Particularly, frequent political changes within the 
government class can develop instability, resulting 
in continuous and different regulations sometimes 
even self-contradictory, thus  affecting the quality 
of the national legislation. We have also to consi-
der that the global economic crisis is altering the 
whole scenario, allowing some developing coun-
tries to became the new entrepreneurs of the 21th 
century.
Given the current and predicted impact of several 
chronic and degenerative diseases in the general 
population, regenerative medicine will provide the 
possibility to cure diseases, prolong and improve 
quality of life, promote economic stimulus, and even 
reduce the cost of medical cares. In few words, it 
would truly provide what we have so long sought: 
a Prometheus of modern times.
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